Skip to main content
. Author manuscript; available in PMC: 2019 May 29.
Published in final edited form as: Cancer Res. 2018 Sep 12;78(23):6680–6690. doi: 10.1158/0008-5472.CAN-17-3878

Figure 5. IMO-8503 treatment protects mice from LLC-induced cancer cachexia.

Figure 5.

(A) Representative diagram of the in vivo experiment. (B) Immunoblotting for Pax7, MyoD, Phospho-JNK and Phospho-p38 performed on gastrocnemius lysates derived from C57/B6 mice injected with LLC cancer cells and treated with IMO-8503 as described in the Material and Methods section. Vinculin was used as a normalizer in order to show equal protein loading. All the gastrocnemius samples of the “B group” were separately analyzed for Pax7 expression in comparison to samples of Groups A and C (below). (C) Lean Mass Index (LMI, left panel) and (Lean + Fat) Mass Index (LFMI, right panel) were determined for mice whose body composition was analyzed through EchoMRI. +, 5 mg/kg/mouse; ++, 25 mg/kg/mouse; ++d, 25 mg/kg/mouse injected starting 10 days after LLC injection. Results are presented as average ± S.D.; Kruskal-Wallis rank sum test was performed for statistical analysis.